Recent therapeutic advances in urothelial carcinoma: A paradigm shift in disease management
| Autor: | Joaquim Bellmunt, Begoña P. Valderrama, Javier Puente, Enrique Grande, M. Victoria Bolós, Nuria Lainez, Sergio Vázquez, Pablo Maroto, Miguel Ángel Climent, Xavier Garcia del Muro, José Ángel Arranz, Ignacio Durán |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: |
Avelumab
Carcinoma Transitional Cell Bladder cancer Disease Management Antibody drug-conjugate (ADC) Hematology Càncer de bufeta Checkpoint inhibitors (CPIs) Switch maintenance Urothelial carcinoma (UC) Oncology Urinary Bladder Neoplasms Humans Immunotherapy Neoplasm Recurrence Local Platinum-based chemotherapy |
| Zdroj: | Dipòsit Digital de la UB Universidad de Barcelona |
| Popis: | Management of first-line advanced urothelial carcinoma (UC) has consisted during the past three decades in the administration of platinum-based chemotherapy followed by observation. Despite moderate to high response rates to first-line treatment, most patients will relapse shortly after and the outcomes with subsequent therapies are poor with 5-year overall survival rates of 5% in the pre-immunotherapy era. Nonetheless, recent therapeutic developments including the paradigm shift of first-line maintenance therapy with avelumab after response or stabilization on platinum-based chemotherapy, along with the incorporation of new drug classes in further lines of treatment such as antibody drug-conjugates and fibroblast growth factor receptor inhibitors have reshaped the field leading to better outcomes in this patient population. This article reviews the current state of the art with an overview on UC management, recent advances, and the upcoming strategies currently in development in advanced UC with an insight into the biology of this disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|